Latest From AbbVie Inc.
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.
Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development and regulatory strategy for BAN2401 in Alzheimer's. And Gilead investors want reassurance that the company will return to growth soon.
Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals...
After years of industry unsuccessfully trying to find an oral version of the successful I.V. integrin inhibitors, Morphic has a prolific platform – and AbbVie is paying $100m up front for preclinical oral integrin inhibitors for fibrosis indications, potentially including NASH.
- Therapeutic Areas
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- North America
- Company Type
- Big Pharma
- Parent & Subsidiaries
- AbbVie Inc.
- Senior Management
Richard A Gonzalez, Chmn. & CEO
William J Chase, EVP, CFO
Michael E Servino, MD, EVP, R&D & CSO
Carlos Alban, EVP, Commercial Ops.
- Contact Info
Phone: (847) 937-6100
1 N. Waukegan Rd.
North Chicago, IL 60064
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.